Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss

Pharmacoepidemiology and Drug Safety

Volumn 26, Issue 7, 2017, Pages 843-852

  McGrogan, Anita ^a   Snowball, Julia ^a   Charlton, Rachel A ^a  

^a University of Bath   (United Kingdom)

Author keywords

GPRD; miscarriage; pregnancy; statins; termination

Indexed keywords

ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIET THERAPY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; SMOKING; SPONTANEOUS ABORTION; CHEMICALLY INDUCED; FACTUAL DATABASE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; PREGNANCY; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 85012292661     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.4176     Document Type: Article

References (15)

1. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ 2015; 350: h1035.
2. Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG 2013; 120: 463–471.
3. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007; 64: 496–509.
4. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 2008; 26: 175–177.
5. Hook EB, Regal RR. Conceptus viability, malformation, and suspect mutagens or teratogens in humans. The Yule-Simpson paradox and implications for inferences of causality in studies of mutagenicity or teratogenicity limited to human livebirths. Teratology 1991; 43: 53–59.
6. Andrews E, Tennis P. Promise and pitfalls of administrative data in evaluating pregnancy outcomes. Pharmacoepidemiol Drug Saf 2007; 16: 1181–1183.
7. Snowball J, de Vries C. Determination of pregnancy on the General Practice Research Database. Pharmacoepidemiol Drug Saf 2007; 16: S118.
8. Dolk H. EUROCAT: 25 years of European surveillance of congenital anomalies. Arch Dis Child Fetal Neonatal Ed 2005; 90: F355–F3F8.
9. McGrogan A, Snowball J, de Vries CS. Pregnancy losses in women with Type 1 or Type 2 diabetes in the UK: an investigation using primary care records. Diabet Med 2014; 31: 357–365.
10. Sammon CJ, Snowball J, McGrogan A, de Vries CS. Evaluating the hazard of foetal death following H1N1 influenza vaccination; a population based cohort study in the UK GPRD. PLoS One 2012; 7: e51734.
11. Charlton RA, Hutchison A, Davis KJ, de Vries CS. Asthma management in pregnancy. PLoS One 2013; 8: e60247.
12. Charlton RA, Weil JG, Cunnington MC, de Vries CS. Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD. Drug Saf 2010; 33: 741–750.
13. Thorogood M, Seed M, De Mott K. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG 2009; 116: 478–479.
14. Pollack PS, Shields KE, Burnett DM, et al. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 2005; 73: 888–896.
15. Lipid modification: cardivoascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease: NICE 2015 Contract No.: CG181.